Covance (NYSE: [[ticker:CVD]]), said today that its genomics laboratory in Seattle has agreed to a new collaboration with the Institute for Systems Biology to study brain tumors, according to GenomeWeb. Researchers will study the genetic differences that lurk within tumors, and find molecular targets that would enable researchers to select the right drug for the right patient. Financial terms weren’t disclosed. Covance arrived in Seattle in July 2009 when it bought the gene expression lab that was part of Merck’s Rosetta Inpharmatics unit.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
